AavantiBio is a gene therapy company backed by a premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences, and RA Capital Management, who led the company’s $107 million Series A financing. Headquartered in Cambridge, Massachusetts, AavantiBio’s platform is focused on advancing innovative gene therapies in areas of high unmet medical need, including a lead program in Friedreich’s Ataxia, a rare inherited genetic disease that causes cardiac and central nervous system dysfunction. The company benefits from strategic partnerships with the University of Florida’s renowned Powell Gene Therapy Center and the MDA Care Center at UF Health where AavantiBio’s co-founders and renowned gene therapy researchers Barry Byrne, M.D., Ph.D. and Manuela Corti, P.T., Ph.D. maintain their research and clinical practices.
We are looking for exceptional individuals who share our passion for developing novel therapies to treat rare diseases and advancing the field of gene transfer therapy. Developing genetic treatments for rare diseases is inspiring but challenging work and it takes dedication and courage which will make a meaningful impact on those who suffer from rare diseases. At AavantiBio, we will push each other to perform at our very best, and build a company that not only our employees are proud of, but also the rare disease community, because everyone knows we are trying to make a difference in patients’ lives. Come join our team!
Company Details
- Employees
- 6
- Address
- 245 1st St., Cambridge,ma,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- aavantibio.com
- Keywords
- Gene Therapy, Biotechnology, Pharmaceuticals, AAV.
- HQ
- Cambridge, MA
Aavantibio, Inc. Questions
Aavantibio, Inc.'s website is aavantibio.com
Aavantibio, Inc.'s LinkedIn profile is https://www.linkedin.com/company/aavantibio
Aavantibio, Inc. has
6 employees.
View email and phone details for 6
employees at Aavantibio, Inc..
Aavantibio, Inc.'s industry is
Biotechnology Research
Aavantibio, Inc.'s top competitors are
Beam Therapeutics,
Vertex Pharmaceuticals,
Spyre Therapeutics,
Intellia Therapeutics, Inc.,
Solid Biosciences,
Verve Therapeutics,
Tessera Therapeutics,
Carbon Biosciences,
Voyager Therapeutics, Inc.,
Sarepta Therapeutics.
Aavantibio, Inc.'s categories are Biotechnology Research
